➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

LASTACAFT Drug Profile

Email this page to a colleague

« Back to Dashboard

Which patents cover Lastacaft, and when can generic versions of Lastacaft launch?

Lastacaft is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcaftadine profile page.

DrugPatentWatch® Generic Entry Outlook for Lastacaft

Lastacaft was eligible for patent challenges on July 28, 2014.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2027. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Drug patent expirations by year for LASTACAFT
Drug Prices for LASTACAFT

See drug prices for LASTACAFT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for LASTACAFT
Generic Entry Date for LASTACAFT*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LASTACAFT

Identify potential brand extensions & 505(b)(2) entrants

ORA, Inc.Phase 4
Starx Research Center, LLCPhase 4

See all LASTACAFT clinical trials

Pharmacology for LASTACAFT
Paragraph IV (Patent) Challenges for LASTACAFT
Tradename Dosage Ingredient NDA Submissiondate
LASTACAFT SOLUTION/DROPS;OPHTHALMIC alcaftadine 022134 2014-07-30

US Patents and Regulatory Information for LASTACAFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.